µ¼Ê¦ÐÕÃû£ºÉòÖ¾É
ÐÔ±ð£ºÄÐ
ÈËÆøÖ¸Êý£º426
ËùÊôԺУ£ºÄþ²¨´óѧ
ËùÊôԺϵ£ºÒ½Ñ§Ôº
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£º
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º¶ú±ÇÑÊºí¿ÆÑ§
Ñо¿ÁìÓò£º ¶ú±ÇÑÊºí¿ÆÑ§
Ñо¿ÁìÓò£º ¶ú±ÇÑÊºí¿ÆÑ§ [ÊÕÆð]
ͨѶ·½Ê½ :
°ì¹«µç»°£º**
µç×ÓÓʼþ£ºszs7216@163.com
ͨѶµØÖ·£ºÄþ²¨ÊÐÐËÄþ·57ºÅ
¸öÈ˼òÊö :
Ö÷ÈÎҽʦ£¬¶þ¼¶¸Úλ½ÌÊÚ£¬¹úÎñÔºÌØÊâ½òÌùר¼Ò£¬ð®³ÇÊ®´óÃûÒ½£»ÏÖÈÎÄþ²¨Êжú±ÇÑÊºí¼²²¡Õï¶ÏÖÎÁÆÖÐÐÄÖ÷ÈΡ¢Äþ²¨ÊÐÒ½ÁÆÖÐÐÄÀî»ÝÀûÒ½Ôº¶ú±ÇÑʺíÍ·¾±Íâ¿ÆÖ÷ÈΡ¢Äþ²¨´óѧҽѧԺ¶ú±ÇÑÊºí¿ÆË¶Ê¿Ñ§Î»µã¸ºÔðÈË¡¢Äþ²¨´óѧ¶ú±ÇÑÊºí¿ÆÑ§½ÌÑÐÊÒÖ÷ÈΣ»ÖйúÖÐÎ÷Ò½½áºÏ¶ú±ÇÑÊºí¿ÆÑ§»á³£Î¯¡¢Õã½Ê¡Ò½Ñ§»á¶ú±ÇÑʺíÍ·¾±Íâ¿ÆöλÔÓéÀֵǼÈë¿ÚÏÂÔØÑ§»á¸±Ö÷ÈÎίԱ¡¢Äþ²¨ÊÐҽѧ»á¶ú±ÇÑÊºí¿ÆöλÔÓéÀֵǼÈë¿ÚÏÂÔØÑ§»áÖ÷ÈÎίԱ¡¢Õã½Ê¡ÖÐÎ÷Ò½½áºÏѧ»á¶ú±Çºí¿Æ·Ö»á¸±Ö÷ÈÎίԱ£¬Äþ²¨Õã½´óѧУÓÑ»áҽѧ·Ö»áÊ׽쳣ÎñÀíÊ£»Öйú¿ÆÑ§Ôº´óѧ²©Ê¿Éúµ¼Ê¦¡¢Äþ²¨´óѧÑʺíÍ·¾±Ö×ÁöÉúÎïҽѧÐÅÏ¢´¦Àí·½Ïò²©Ê¿Éúµ¼Ê¦¡¢Äþ²¨´óѧͷ¾±Íâ¿ÆË¶Ê¿Éúµ¼Ê¦¡¢Õã½´óѧ¼æÖ°Ë¶Ê¿Éúµ¼Ê¦£»¹ú¼ÊSCIÆÚ¿¯¡¶Medical Science Monitor¡·£¨Ó°ÏìÒò×Ó£º1.58£©ÌØÔ¼Éó¸åÈË,¡¶Öлª¶ú¿ÆÑ§ÔÓÖ¾¡·¼°¡¶ÏÖ´úʵÓÃҽѧ¡·±àί¡£
×÷ΪʡÊй²½¨Ò½Ñ§Öصãѧ¿Æ´øÍ·ÈË¡¢Äþ²¨ÊÐÁÙ´²ÌØÉ«Öصãר¿Æ´øÍ·ÈË¡¢Äþ²¨ÊÐÓÅÐãѧ¿Æ´øÍ·ÈË¡¢Äþ²¨ÊС°4321È˲ʤ³Ì¡±µÚÒ»²ã´ÎÈ˲ţ¬´øÁìÀî»ÝÀûÒ½Ôº¶ú±ÇÑʺíÍ·¾±Íâ¿ÆÍŶÓÁ¬ÐøÈýÂÖ»ñÄþ²¨ÊÐÒ½Ñ§ÖØµã½¨Éèѧ¿Æ£¬2015ÄêÊ¡ÎÀ¼ÆÎ¯×¨¼Ò×éÔÚð®ÉܼÎÈýÊÐ15¸öÊ¡Êй²½¨Öصãѧ¿ÆÖÕÆÚÆÀÉ󣬻ñµÃÓÅÐ㣨85·Ö£©£¬ÃûÁеÚÒ»£¬²¢»ñµÃ2016ÄêÐÂÒ»ÂÖÊ¡Êй²½¨Öصãѧ¿Æ£»ÁÙ´²ÌØÉ«×¨¿ÆÖÐÆÚÆÀ¹ÀÒàΪÓÅÐã¡£
¿ªÍØ´´Ð£¬ÕÆÎÕ¹úÄÚÍâ×îж¯Ì¬£¬½Ó¹ì±±¾©¡¢ÉϺ£¡£¿ªÕ¹Ê¡ÄÚÁìÏȹúÄÚÏȽøµÄм¼ÊõÐÂÏîÄ¿£¬ÌرðÊǹúÄÚÊ״οªÕ¹Éà°êÖØ½¨ÏÂÑÊ¡¢¶þǻһµÀ¼¼Êõ¼°Ë«²àÈ˹¤¶úÎÏͬʱֲÈëÊõ£»Ê¡ÄÚÂÊÏÈ¿ªÕ¹Á˶ú±ÇÏà¹ØµÄµ×Ö×ÁöÇгý£¬²¢½¨Á¢Á˵×ÖØ½¨ÏµÁÐÊõʽ£¬¿ªÍØÁËÉúÃü½ûÇøÊÖÊõµÄо³½ç£¬²¢»ñµÃÏà¹Ø¿Æ¼¼³É¹û½±3Ïî¡£½üÄêÀ´£¬ÒýÈë΢Ѫ¹Ü·ìºÏ¼¼Êõ£¬Ê¡ÄÚÂÊÏÈ¿ªÕ¹Á˶àÖÖÓÎÀë×éÖ¯°êÐÞ¸´ÏÂÑÊ¡¢ºí¼°¾±¶Îʳ¹Ü£¬´ó´óÌá¸ßÁËÍíÆÚºí°©ÏÂÑʰ©µÄÉú´æÂʼ°Éú´æÖÊÁ¿£¬Ê¹Äþ²¨ÊÐÑʺíÍ·¾±Íâ¿Æ¿çÈë¹úÄÚÏȽøÐÐÁС£Îª´Ë£¬¾Ù°ìÁË4Ïî8ÆÚ¹ú¼Ò¼¶¼ÌÐø½ÌÓýѧϰ°à£¬Íƹãм¼Êõ¡£
ÖØÊÓ¼²²¡µÄÁÙ´²¼°»ù´¡Ñо¿£¬½ü5ÄêÏȺóÖ÷³ÖÍê³ÉÊ¡¼¶¿ÎÌâ2Ï˳ÀûÍê³ÉÄþ²¨ÊÐÖØ´ó£¨Öص㣩¿Æ¼¼¹¥¹ØÏîÄ¿2ÏÆäÖÐ2016Äê12ÔÂÍê³ÉµÄÖØ´óÏîÄ¿ÒÔ38ƪÂÛÎÄ£¨20ƪSCIÂÛÎÄÓ°ÏìÒò×Ó´ï73.317£©£¬5Ïî·¢Ã÷רÀû±»Ê¡ÄÚÍâר¼Ò¼ø¶¨Îª¹ú¼ÊÏȽø£¬²¢»ñµÃ2017ÄêʡҽҩÎÀÉú¿Æ¼¼½±¶þµÈ½±£»Íê³ÉÊÐÌü¼¶ÏîÄ¿3ÏºÏ×÷Íê³É¿Æ¼¼²¿¡°Ê®Ò»Î塱¿Æ¼¼Ö§³Å¼Æ»®ÏîÄ¿1ÏĿǰ³Ðµ£Ê¡¼¶ÏîÄ¿2ÏÄþ²¨ÊпƼ¼´´ÐÂÍŶÓ1ÏÒÔµÚ¶þ³Ðµ£ÈË»ñ¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð2Ï¹²»ñ¿ÆÑо·ÑÔ¼450ÍòÔª¡£ÏȺóÖ÷°ì4Ïî8ÆÚ¹ú¼Ò¼¶¡¢5Ïî10ÆÚÊ¡¼¶Ò½Ñ§¼ÌÐø½ÌÓýÅàѵ°à£»Ã¿ÄêÖ÷°ìÄþ²¨ÊÐҽѧ»á¶ú±ÇÑÊºí¿ÆÑ§ÊõÄê»á£»¾Ù°ì3´Îº£Ï¿Á½°¶¡¢1´Îð®¸Û¶ú±ÇÑÊºí¿ÆÑ§ÂÛ̳£»Ã¿Äê²ÎÓëѧÊõ½²×ù5~6´Î£¬¹ú¼Ê½»Á÷1~2´Î£¬°ÑÑо¿³É¹ûÍÆ¹ãµ½ÒµÄÚͬÐС£
ÒÔµÚÒ»ÅÅÃû»ñÊ¡¼¶¿Æ¼¼½ø²½½±1ÏʡÌü¼¶¿Æ¼¼´´Ð½±7ÏÊм¶¿Æ¼¼½ø²½½±5ÏÆäÖÐ2015Äê»ñÕã½Ê¡¿Æ¼¼½ø²½ÈýµÈ½±£¬2017Äê»ñÕã½Ê¡Ò½Ò©ÎÀÉú¿Æ¼¼½ø²½¶þµÈ½±£¬2013Äê»ñÄþ²¨ÊпƼ¼½ø²½Ò»µÈ½±£»ÒÔµÚÒ»×÷Õß»òͨÐÅ×÷Õß·¢±íÂÛÎÄ66ƪ£¬ÆäÖÐSCIÂÛÎÄ23ƪ£¬Ó°ÏìÒò×ӺϼÆÔ¼46.75£¬ÆäÖÐ2ƪÂÛÎÄ»ñÄþ²¨ÊÐ×ÔÈ»¿ÆÑ§ÓÅÐãÂÛÎÄÒ»µÈ½±ºÍÈýµÈ½±¡£ÉêÇë¹ú¼Ò·¢Ã÷רÀû5ÏÆäÖÐ1ÏîÒÑÊÚȨ¡£²Î±àÄÏ·½³ö°æÉç³ö°æµÄ¡¶µ±´úÍâ¿ÆÑ§¡·£¬ÕýÔڲαàÓÉ¿ÆÑ§³ö°æÉç³ö°æµÄ¡¶ÁÙ´²±ê×¼½â¶Á´ÔÊé¡·¡£ÅàÑø²©Ê¿Ñо¿Éú1Ãû¡¢Ë¶Ê¿Ñо¿Éú20Ãû£¨ÆäÖÐ13Ãû±ÏÒµ¹¤×÷£¬7ÃûÔÚ¶Á£©¡£
¿ÆÑй¤×÷ :
1£©Shen Z*, Li Q, Deng H, Lu D, Song H, Guo J. Long non-coding RNA profiling in laryngeal squamous cell carcinoma and its clinical significance: potential biomarkers for LSCC.PLoS One.20149(9):e108237.IF=3.234
2£©Shen, Z.-S(*). Cui, X. Hou, R.-X. Li, Q. Deng, H.-X. Fu, J(*).Tough biodegradable chitosan-gelatin hydrogels via in situ precipitation for potential cartilage tissue engineering.RSC Advances,2015, 5 (69), 55640-55647. SCIÓ°ÏìÒò×Ó£º3.84
3£©Shen Z*, Zhou C, Li J, Ye D, Deng H, Cao B, Hao W, Lin L, Zhang Y*.SHISA3 Promoter Methylation Is a Potential Diagnostic and Prognostic Biomarker for Laryngeal Squamous Cell Carcinoma.Biomed Res Int. **.SCIÓ°ÏìÒò×Ó£º2.134
4£©Zhisen Shen*,Bing Cao,Lexi Lin,Chongchang Zhou,Dong Ye,Shijie Qiu,Qun Li,Xiang Cui.The Clinical Signification of Claudin-11 Promoter Hypermethylation for Laryngeal Squamous Cell Carcinoma.Med Sci Monit. 201723:3635-3640.SCIÓ°ÏìÒò×Ó£º1.585
5£©Shen Z*, Chen X#, Li Q, Ye H, Li J, Zhou C, Duan S*.TGFB2 and BCL2L11 methylation in male laryngeal cancer patients. Oncology Letters. 2016,12(4):2999-3003, SCIÓ°ÏìÒò×Ó£º1.554
6£©Shen Z*, Zhou C, Li J, Deng H, Li Q, Wang J.The association, clinicopathological significance, and diagnostic value of CDH1 promoter methylation in head and neck squamous cell carcinoma: a meta-analysis of 23 studies.Onco Targets Ther.2016,9:6763-6773. SCIÓ°ÏìÒò×Ó£º2.272
7£©Shen Z(*), Zhou C, Li J, Ye D, Li Q, Wang J, Cui X, Chen X, Bao T, Duan S(*).Promoter hypermethylation of miR-34a contributes to the risk, progression, metastasis and poor survival of laryngeal squamous cell carcinoma.Gene. 2016,S0378-1119(16)30573-X. SCIÓ°ÏìÒò×Ó£º2.319
8£©Shen Z(*), Chen X, Li Q, Zhou C, Xu Y, Yu R, Ye H, Li J, Duan S. Elevated methylation of CMTM3 promoter in the male laryngeal squamous cell carcinoma patients.Clin Biochem. 2016 pii: S0009-9120(16)30181-3. SCIÓ°ÏìÒò×Ó£º2.382
9£©Shen Z(*), Chen X, Li Q, Zhou C, Li J, Ye H, Duan S(*). SSTR2 promoter hypermethylation is associated with the risk and progression of laryngeal squamous cell carcinoma in males. Diagn Pathol. 201611(1):10. SCIÓ°ÏìÒò×Ó£º2.597
10£©Shen Z(*), Wang J, Lu D, Li Q, Zhou C, Zhu Y(*), Hu X.Synthesis and Properties of Flexible Polyurethane Using Ferric Catalyst for Hypopharyngeal Tissue Engineering.Biomed Res Int.2015:798721. SCIÓ°ÏìÒò×Ó£º1.579
11£©Shen Z(*), Lu D, Li Q, Zhang Z, Zhu Y(*). Synthesis and characterization of biodegradable polyurethane for hypopharyngeal tissue engineering.Biomed Res Int£¬2015:871202. SCIÓ°ÏìÒò×Ó£º1.579
12£©Shen Z*, Kang C, Chen JJ, Ye D, Qiu SJ, Guo SS, Zhu YB. Surface modification of polyurethane towards promoting the ex vivo cytocompatibility and in vivo biocompatibility for hypopharyngeal tissue engineering.J Biomater Appl.201328(4):607-616.IF=2.197
13£©Shen Z*, Zhan G, Deng H, Ren Y, Ye D, Xiao B, Guo J. MicroRNA-519a demonstrates a significant tumor suppressive activity in laryngeal squamous cells by targeting anti-carcinoma HuR gene.J Laryngol Otol.**(12):1194-1202.IF=0.672
14£©Shen Z*, Guo S, Ye D, Chen J, Kang C, Qiu S, Lu D, Li Q, Xu K, Lv J, Zhu Y. Skeletal muscle regeneration on protein-grafted and microchannel-patterned scaffold for hypopharyngeal tissue engineering.Biomed Res Int.2013:146953.IF=1.579
15£©Shen Z*, Chen J, Kang C, Gong, Zhu Y. Engineered hypopharynx from coculture of epithelial cells and fibroblasts using poly(ester urethane) as substratum.Biomed Res Int.2013:138504.IF=1.579
16£©Shen Z*, Zhan G, Ye D, Ren Y, Cheng L, Wu Z, Guo J. MicroRNA-34a affect the occult of laryngeal squamous cell carcinoma by targeting anti-apoptotic gene surviving.Med Oncol.2012,29(4):2473-2480.IF=2.634
17£©Shen Z*, Zheng J, Chen B, Peng G, Zhang T, Gong S, Zhu Y, Zhang C, Li R, Yang L, Zhou J, Cai T, Jin L, Lu J, Guan MX. Frequency and spectrum of mitochondrial 12S rRNA variants in 440 Han Chinese subjects with aminoglycoside-induced and nonsyndromic hearing loss.J Transl Med.20119:4.IF=3.93
18£©Shen Z*, Jiang Z, Ye D, Xiao B, Zhang X, Guo J. Growth inhibitory effects of DJ-1-small interfering RNA on laryngeal carcinoma Hep-2 cells.Med Oncol.201128(2):601-607.IF=2.634
19£©Shen Z*, Ren Y, Ye D, Guo J, Kang C, Ding H. Significance and relationship between DJ-1 gene and survivin gene expression in laryngeal carcinoma.Eur J Histochem.201155(1):e9.IF=2.042
20£©Shen Z*, Ye D, Zhang X, Jiang Z, Xiao B, Guo J. Inhibitory effect of HuR gene small interfering RNA segment on laryngeal carcinoma Hep-2 cell growth.J Laryngol Otol.**(11):1183-1189.IF=0.672
21£©Yu XWu YLiu YDeng HShen Z*Xiao BGuo J.miR-21, miR-106b and miR-375 as Novel Potential Biomarkers for LaryngealSquamous Cell Carcinoma£¬Curr Pharm Biotechnol£¬201415(5):503-8¡£SCIÓ°ÏìÒò×Ó£º2.511£»£¨Í¨Ñ¶×÷Õߣ©
22£©Ye D, Shen Z(*), Wang G, Deng H, Qiu S, Zhang Y. Analysis of factors in successful nasal endoscopic resection of nasopharyngeal angiofibroma. Acta Otolaryngol. 2015,23:1-9SCIÓ°ÏìÒò×Ó£º1.13
23£©Shijie Qiu,Zhaoxia Xia,Qun Li,Dong Ye,Qi Huang,Zhisen Shen*. Expression and clinical significance of YAP in laryngeal squamous cell carcinoma patients.ONCOLOGY LETTERS, 2017,13(3):1311-1314. SCIÓ°ÏìÒò×Ó£º1.482
24£©ÉòÖ¾É*,µËºìϼ,Ò¶¶°,ÕŽ¨,ôÃÊÀ½Ü,ÀîȺ,´ÞÏè.RNA¸ÉÈųÁĬDJ-1»ùÒò¶ÔÈËºí°©AMC-HN-8ÂãÊóÒÆÖ²ÁöÉú³¤µÄÓ°Ïì¼°»úÖÆÌ½ÌÖ.Õã½´óѧѧ±¨(ҽѧ°æ).2016,45(4):349-355
25£©ÉòÖ¾É,³ÉÁ¢ÐÂ,ÚùÕñ»ª,ôÃÊÀ½Ü,ÑîÇýÔÆ,Ò¶¶°.Àæ×´ÎѰ©ÊõºóÐÞ¸´Óë×ÛºÏÖÎÁÆÁÆÐ§·ÖÎö,Õã½Ò½Ñ§,2012,34(6):412-414,463.
26£©ÉòÖ¾É,Õ²¹úÎÄ,µËºìϼ,¿µ³Ò,¹ù¿¡Ã÷.΢СRNA-519b-3p¶ÔÈËºí°©Hep-2ϸ°ûÔöÖ³µÄÒÖÖÆ×÷Óü°Æä»úÖÆ,Öлª¶ú±ÇÑʺíÍ·¾±Íâ¿ÆÔÓÖ¾,2014,49(2):151-156.
27£©³Â¾²¾²,ÉòÖ¾É,¹®³¤·ï,¿µ³Ò,óÃÑDZó.¹Ç÷À¼¡ÎÀÐÇϸ°ûµÄÅàÑø¼°ÆäÔÚ¹Ç÷À¼¡×éÖ¯¹¤³ÌÑо¿ÖеÄÓ¦ÓÃ,ÖйúÉúÎïҽѧ¹¤³Ìѧ±¨,2011,30(6):955-960.
28£©³Â¾²¾²,ÉòÖ¾É,óÃÑDZó,¿µ³Ò.ÈËÑÊËõ¼¡Ï¸°ûÌåÍ⸴ºÏÅàÑøµÄÑо¿,ҽѧÑо¿ÔÓÖ¾,2013,42(3):85-89.
29£©¿µ³Ò,ÉòÖ¾É,³Â¾²¾²,óÃÑDZó.±íÃæ¸ÄÐÔ¾Û°±õ¥Æ½ÃæÄ¤ÓëÌåÍâÈËÏÂÑʳÉÏËάϸ°ûÏàÈÝÐÔÑо¿,Öйú×éÖ¯¹¤³ÌÑо¿,2013.34:6131-6137.
30£©¿µ³Ò,ÉòÖ¾É,³Â¾²¾²,óÃÑDZó.Ò½Óþ۰±õ¥¶à¿×Ö§¼ÜµÄÖÆ±¸¼°ÆäÓëϸ°û¹²ÅàÑøµÄÑо¿,ҽѧÑо¿ÔÓÖ¾,2013,42(5):201-204.
31£©¹ùɺɺ,ÉòÖ¾É,½´ïïÇ,¹®³¤·ï,óÃÑDZó.¸Éϸ°ûÏò¹Ç÷À¼¡Ï¸°ûµÄÓÕµ¼·Ö»¯¼°ÆäÔÚÖÎÁƹÇ÷À¼¡²¡±äÖеÄÓ¦ÓÃ,Öйúϸ°ûÉúÎïѧѧ±¨,2015£¬37£¨1£©£º124-131.
32£©¹ùɺɺ,ÉòÖ¾É,³Â¾²¾²,¿µ³Ò,ôÃÊÀ½Ü,Ò¶¶°,ÈÎÔ¶.ÏÂÑʱڹ¤³Ì»¯ÑÊËõ¼¡µÄÐÎ̬¹Û²ìÓ빦ÄÜÑо¿,ҽѧÑо¿ÔÓÖ¾,2013,42(8):88-91.
33£©Â½´ïïÇ,ÉòÖ¾É,ºîÈðϼ,¸¶¿¡,ÀîȺ,µËºìϼ.ºíÈí¹ÇÖ§¼Ü½á¹¹Óë¹¹½¨µÄÑо¿½øÕ¹,±±¾©ÉúÎïҽѧ¹¤³Ì,2014,33(2):191-196.
34£©ÀîȺ,½´ïïÇ,´ÞÏè,ÏÄÌì,ÉòÖ¾É,¹ù¿¡Ã÷.·Ç±àÂëRNAÔÚºí°©·¢ÉúÖеÄ×÷Óü°ÆäÁÙ´²ÒâÒå,Öйúϸ°ûÉúÎïѧѧ±¨,2013, 35(12):1797¨C1805.
35£©ºÂÎľêÉòÖ¾É*ÀîȺ¹ù¿¡Ã÷*.»·×´RNAÔÚÍ·¾±²¿Ö×ÁöÖеÄ×÷ÓÃ.Öйúϸ°ûÉúÎïѧѧ±¨.2017, 39(1): 97-105
37£©Íõ½£´ÞÏèÀîȺ³ÂÉù²ÓÉòÖ¾É(*),¹ù¿¡Ã÷(*)£»ºí°©»¼ÕßѪ½¬¼°×éÖ¯Öг¤Á´·Ç±àÂëRNAµÄ¼ì²â¼°ÁÙ´²ÒâÒå.Äþ²¨´óѧѧ±¨(Àí¹¤°æ).2016,29(3):123-127
38£©´ÞÏèºîÈðϼÀîȺ½´ï¿¬µËºìϼÉòÖ¾É(*).¿Ç¾ÛÌÇÔÚºíÈí¹Ç×éÖ¯¹¤³ÌÖеÄÓ¦ÓÃ.×éÖ¯¹¤³ÌÓëÖØ½¨Íâ¿ÆÔÓÖ¾. 2015,11(3):208-212£»
1¡¢ÖйúÖÐÎ÷Ò½½áºÏ¶ú±ÇÑÊºí¿ÆÑ§»á³£Î¯£»
2¡¢Õã½Ê¡Ò½Ñ§»á¶ú±ÇÑʺíÍ·¾±Íâ¿ÆöλÔÓéÀֵǼÈë¿ÚÏÂÔØÑ§»á¸±Ö÷ÈÎίԱ£»
3¡¢Äþ²¨ÊÐҽѧ»á¶ú±ÇÑÊºí¿ÆöλÔÓéÀֵǼÈë¿ÚÏÂÔØÑ§»áÖ÷ÈÎίԱ£»
4¡¢Õã½Ê¡ÖÐÎ÷Ò½½áºÏѧ»á¶ú±Çºí¿Æ·Ö»á¸±Ö÷ÈÎίԱ¡£
1£©Õã½Ê¡×ÔÈ»¿ÆÑ§»ù½ð£¬¡°ºí°©Ïà¹ØÐÔÃô¸Ð³¤Á´·Ç±àÂëRNAɸѡ¼°×÷ÓûúÖÆÌ½ÌÖ£¨±àºÅ£ºLY14H160003£©¡±£»Ê±¼ä£º2014Äê1ÔÂ~2016Äê12Ô£»Ö÷³Ö£»
2£©Õã½Ê¡Ò½Ò©ÎÀÉúÊ¡²¿ÅàÓý¼Æ»®£¬¡°É¸Ñ¡ºóÃô¸Ð³¤Á´·Ç±àÂëRNA×÷ÓûúÖÆÓëºí°©·¢Éú¡¢·¢Õ¹¼°Ô¤ºó¹ØÏµÑо¿£¨±àºÅ£º2014PYA017£©¡±£»Ê±¼ä£º2014Äê6ÔÂ~2017Äê6Ô£»Ö÷³Ö£»
3£©Õã½Ê¡Ò½Ò©ÎÀÉúƽ̨Ñо¿¼Æ»®ÖصãÏîÄ¿£¬¡°HuR»ùÒòÔÚºí°©·¢²¡¡¢½øÕ¹ºÍ¸´·¢»úÖÆ¼°ÆäÓëÔ¤ºó¹ØÏµµÄÑо¿£¨±àºÅ£º2012ZDAO42£©¡±£»Ê±¼ä£º2012Äê7ÔÂ~2015Äê7Ô£»Ö÷³Ö£»
4£©Äþ²¨ÊÐÖØ´ó£¨Öص㣩¿Æ¼¼¹¥¹Ø¼Æ»®£¬¡°È˹¤×éÖ¯°ê¹¹½¨¼°ÆäÔÚºí°©ÏÂÑʰ©ÊõºóÐÞ¸´Öлù´¡ÓëÁÙ´²Ó¦ÓÃÑо¿£¨±àºÅ£º2012C5015£©¡±£»Ê±¼ä£º2012Äê9ÔÂ~2015Äê8Ô£»Ö÷³Ö£»
5£©Äþ²¨ÊпƼ¼´´ÐÂÍŶӣ¬¡°ÑʺíÍ·¾±¶ñÐÔÖ×ÁöÕïÖδ´ÐÂÍŶӣ¨±àºÅ£º2012B82019£©¡±Ê±¼ä£º2012Äê9ÔÂ~2017Äê12Ô£»Ö÷³Ö£»
6£©Äþ²¨ÊÐ×ÔÈ»¿ÆÑ§»ù½ð£¬¡°DJ-1»ùÒòÔÚºí°©·¢²¡¡¢½øÕ¹ºÍ¸´·¢»úÖÆ¼°ÆäÓëÔ¤ºó¹ØÏµµÄÑо¿£¨±àºÅ£º2012A610208£©¡±£¬Ê±¼ä£º2012Äê9ÔÂ~2013Äê12Ô£»Ö÷³Ö£»
7£©¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð£¬¡°¸Éϸ°û¼¼Êõ¹¹½¨¾ß×é֯ѧ½á¹¹µÄ¹¤³Ì»¯Ê³µÀ¼°ÆäÔÚ¶¯ÎïÌåÄÚÔλÐÞ¸´µÄ»úÖÆ£¨±àºÅ£º**£©¡±£»Ê±¼ä£º2015Äê1ÔÂ~2018Äê12Ô£»µÚ2²ÎÓ룻
8£©¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð£¬¡°Ê³¹ÜÄÚ»·Íâ×ÝÆ½»¬¼¡²ãµÄ¹¹½¨¼°ÆäÔÚ¶¯ÎïÌåÄÚÅàÓýµÄÑо¿£¨±àºÅ£º**£©¡±£»Ê±¼ä£º2012Äê1ÔÂ~2015Äê12Ô£»×ÊÖú£º59ÍòÔª£»µÚ2²ÎÓ룻
9£©Äþ²¨ÊÐÅ©´å¿Æ¼¼´´Ð´´Òµ×ʽðÏîÄ¿£¬¡°¶ú±ÇÑÊºí¿ÆÐ¼¼ÊõÔÚÏçÕòÇøÏØÒ½ÔºµÄÍÆ¹ãÓ¦Ó㨱àºÅ£º2010C91041£©¡±£¬Ê±¼ä£º2010Äê7ÔÂ~2013Äê7Ô£»Ö÷³Ö£»
10£©Äþ²¨ÊÐÖØ´ó£¨Öص㣩¿Æ¼¼¹¥¹Ø¼Æ»®£¬¡°ºí°©ÏÂÑʰ©»ù´¡ÓëÁÙ´²ÐÎ̬¹¦ÄÜÖØ½¨ÏµÁÐÑо¿£¨±àºÅ£º2008C50019£©¡±£¬Ê±¼ä£º2008Äê1ÔÂ~2011Äê12Ô£»Ö÷³Ö£»
1¡¢»ñ½±£º
£¨1£©Õã½Ê¡Ò½Ò©ÎÀÉú¿Æ¼¼½±¶þµÈ½±£¬È˹¤×éÖ¯°ê¹¹½¨¼°ÆäÔÚºí°©ÏÂÑʰ©ÊõºóÐÞ¸´Öлù´¡ÓëÁÙ´²Ó¦ÓÃÑо¿£¬2017Äꣻ
£¨2£©Õã½Ê¡¿Æ¼¼½ø²½ÈýµÈ½±£¬ºí°©ÏÂÑʰ©»ù´¡ÓëÁÙ´²ÐÎ̬¹¦ÄÜÖØ½¨ÏµÁÐÑо¿£¨±àºÅ£ºJ**£©£¬2015Äꣻ
£¨3£©Äþ²¨ÊпÆÑ§¼¼Êõ½ø²½Ò»µÈ½±£¬ºí°©ÏÂÑʰ©»ù´¡ÓëÁÙ´²ÐÎ̬¹¦ÄÜÖØ½¨ÏµÁÐÑо¿£¨±àºÅ£º130110-2£©£¬2014Äꣻ
£¨4£©Õã½Ê¡Ò½Ò©ÎÀÉú¿Æ¼¼¶þµÈ½±£¬ºí°©ÏÂÑʰ©»ù´¡ÓëÁÙ´²ÐÎ̬¹¦ÄÜÖØ½¨ÏµÁÐÑо¿£¨±àºÅ£º12044£©£¬2012Äꣻ
£¨5£©Äþ²¨ÊпÆÑ§¼¼Êõ½ø²½½±¶þµÈ½±£¬¶ú±ÇÏà¹ØÊÖÊõºóµ×ÖØ½¨·½·¨µÄÑо¿£¨±àºÅ£º070218£©£¬2008Äꣻ
£¨6£©Õã½Ê¡Ò½Ò©ÎÀÉú¿Æ¼¼´´Ð¶þµÈ½±£¬¶ú±ÇÏà¹ØÊÖÊõºóµ×ÖØ½¨·½·¨µÄÑо¿£¨±àºÅ£º07047£©£¬2007Äꣻ
£¨7£©Äþ²¨ÊпÆÑ§¼¼Êõ½ø²½ÈýµÈ½±£¬Âµ×Ö×ÁöµÄÏÔ΢Íâ¿ÆÖÎÁƼ°Ð¼¼ÊõÓ¦Ó㨱àºÅ£ºNK060329-3£©£¬2006Äꣻ
£¨8£©Äþ²¨ÊпÆÑ§¼¼Êõ½ø²½ÈýµÈ½±£¬ºí°©ÏÂÑʰ©ÊõºóÏÂÑʼ°¾±¶Îʳ¹ÜȱËðÐÞ¸´·½·¨µÄÑо¿£¨±àºÅ£º**£©£¬2004Äꣻ
£¨9£©Õã½Ê¡Ò½Ò©ÎÀÉú¿Æ¼¼´´ÐÂÈýµÈ½±£¬ºí°©ÏÂÑʰ©ÊõºóÏÂÑʼ°¾±¶Îʳ¹ÜȱËðÐÞ¸´·½·¨µÄÑо¿£¨±àºÅ£º03083£©£¬2003Äꣻ
£¨10£©Õã½Ê¡Ò½Ò©ÎÀÉú¿Æ¼¼´´ÐÂÈýµÈ½±£¬¸ÄÁ¼»áÑáºí³ÉÐÎÊõµÄÑо¿£¨±àºÅ£º01087£©£¬2001Äꣻ
£¨11£©Õã½Ê¡ÎÀÉúÌü¶þµÈ½±£¬Éà°êÖØ½¨ÏÂÑÊ£¬2000Äꣻ
£¨12£©Äþ²¨ÊпÆÑ§¼¼Êõ½ø²½½±ÓÅÐã½±£¬¾Ç°ÂÎѵ×ӲĤÍâÈë·ÏÔ΢Íâ¿ÆÊÖÊõÇгýµ×ÁÚ½ü²¿Ö×Áö£¨±àºÅ£º**£©£¬2003Ä꣬ÅÅÃûµÚ2£»
£¨13£©Õã½Ê¡Ò½Ò©ÎÀÉú¿Æ¼¼´´ÐÂÈýµÈ½±£¬¾Ç°ÂÎѵ×ӲĤÍâÈë·ÏÔ΢Íâ¿ÆÊÖÊõÇгýµ×ÁÚ½ü²¿Ö×Áö£¨±àºÅ£º02104£©£¬2002Ä꣬ÅÅÃûµÚ2¡£
£¨14£©2013-2014Äê¶ÈÄþ²¨ÊÐ×ÔÈ»¿ÆÑ§ÓÅÐãÂÛÎÄÈýµÈ½±£¬ºíÁÛ״ϸ°û°©³¤Á´·Ç±àÂëRNA±í´ïÆ×¼°ÆäÁÙ´²ÒâÒå·ÖÎö£ººíÁÛ״ϸ°û°©µÄDZÔÚÉúÎï±ê¼ÇÎ2015Äꣻ
£¨15£©2011~2012Äê¶ÈÄþ²¨ÊÐ×ÔÈ»¿ÆÑ§ÓÅÐãÂÛÎÄÒ»µÈ½±£¬Frequency and spectrum of mitochondrial 12S rRNA variants in 440 Han Chinese hearing impaired pediatric subjects from two otology clinics£¨±àºÅ£º**£©£¬2013Äꣻ
2¡¢×¨Àû£º
(1)Ò»ÖÖ¸ßÇ¿¶È¿É½µ½âÈí¹Ç×éÖ¯¹¤³ÌÖ§¼Ü¼°ÆäÖÆ±¸·½·¨£¨×¨ÀûºÅ£ºZL 2015 1 **.6£©£»»ñµÃÕߣºÉò־ɡ¢´ÞÏè¡¢¸¶¿¡£»
(2)Ò»ÖÖÇ×Ë®ÐÔ¡¢¿É½µ½âµÄǶ¶Î¾Û°±õ¥¼°ÆäÖÆ±¸·½·¨ºÍÓÃ;£¨ÉêÇëºÅ£º**7.6£©£»»ñµÃÕߣºÉò־ɡ¢Íõ½£¡¢óÃÑDZó£»
(3)¿ÉÓÃÓÚ¼ì²âÓëºí°©Ïà¹ØµÄESRRG»ùÒòÆô¶¯×ÓÇø¼×»ù»¯³Ì¶ÈµÄÊÔ¼ÁºÐ¼°ÆäÓ¦Óã¨ÉêÇëºÅ£º**3.4£©£»»ñµÃÕߣºÉò־ɡ¢ÖÜÖØ²ý£»
(4)¿ÉÓÃÓÚ¼ì²âÓëºí°©Ïà¹ØµÄSHISA3»ùÒòÆô¶¯×ÓÇø¼×»ù»¯³Ì¶ÈµÄÊÔ¼ÁºÐ¼°ÆäÓ¦Óã¨ÉêÇëºÅ£º**3.7£©£»»ñµÃÕߣºÉò־ɡ¢ÖÜÖØ²ý£»
(5)Ò»ÖÖ×éÖ¯¹¤³Ì»¯µÄÈ˹¤ÏÂÑʰêĤµÄÖÆ±¸·½·¨£¨ÉêÇëºÅ£º**5.5£©£»»ñµÃÕߣºÉò־ɡ¢óÃÑDZó¡¢Íõ½£¡£
3¡¢½Ì²Ä£º
µ±´úÍâ¿ÆÑ§Current Surgery£¨µÚÆßÕ£¬ÑÊºí¡ª¡ªÍ·¾±Íâ¿ÆÑ§£©£¬ÄÏ·½³ö°æÉ磬³ö°æÊ±¼ä£º2011Äê12Ô£»ÊéºÅ£ºISBN 978-7-5501-0244-6£»
Äþ²¨´óѧöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÉòÖ¾É
±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø/2019-05-27
Ïà¹Ø»°Ìâ/Ò½Ò©ÎÀÉú ×éÖ¯ Íâ¿Æ ¹¤³Ì ÁÙ´²
ºÓ±±½¨Öþ¹¤³ÌѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÁõÖÙÑó\n
µ¼Ê¦ÐÕÃû£ºÁõÖÙÑóÐÔ±ð£ºÈËÆøÖ¸Êý£º1077ËùÊôԺУ£ººÓ±±½¨Öþ¹¤³ÌѧԺËùÊôԺϵ£ºÍÁľ¹¤³ÌѧԺְ³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º·ÀÔÖ¼õÔÖ¹¤³Ì¼°·À»¤¹¤³ÌÑо¿ÁìÓò£º×°Åäʽ¸Ö½á¹¹¹¤³ÌµÄÉè¼ÆÓ뿹Õ𣻽¨Öþ¸Ö½á¹¹¿É¿¿ÐÔ¼ø¶¨£»BIM¼¼ÊõÓ빤³ÌÉè¼ÆÑо¿ÁìÓò£º×°Åäʽ¸Ö½á¹¹¹¤³ÌµÄÉè¼ÆÓ뿹Õ𣻽¨Öþ¸Ö½á¹¹¿É¿¿ÐÔ¼ø¶¨£»BIM¼¼ÊõÓ빤³Ì ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖÙâýũҵ¹¤³ÌѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÑîÁé
µ¼Ê¦ÐÕÃû£ºÑîÁéÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º918ËùÊôԺУ£ºÖÙâýũҵ¹¤³ÌѧԺËùÊôԺϵ£ºÐÅÏ¢¿ÆÑ§Óë¼¼ÊõѧԺְ³Æ£º¸±Ñо¿Ô±µ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÊ³Æ·°²È«ÓëÖÇÄÜ¿ØÖÆÑо¿ÁìÓò£ºÅ©ÒµÎïÁªÍø¡¢Å©Òµ´óÊý¾Ý¡¢Ê³Æ·°²È«ËÝÔ´¼¼ÊõÑо¿ÁìÓò£ºÅ©ÒµÎïÁªÍø¡¢Å©Òµ´óÊý¾Ý¡¢Ê³Æ·°²È«ËÝÔ´¼¼Êõ[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£ºyang9 ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖÙâýũҵ¹¤³ÌѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-Áõ¹¦Á¼
µ¼Ê¦ÐÕÃû£ºÁõ¹¦Á¼ÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º568ËùÊôԺУ£ºÖÙâýũҵ¹¤³ÌѧԺËùÊôԺϵ£ºÇṤʳƷѧԺְ³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÊ³Æ·¼Ó¹¤Ó밲ȫÑо¿ÁìÓò£ºÊ³Æ··¢½ÍÓëÄðÔìÑо¿ÁìÓò£ºÊ³Æ··¢½ÍÓëÄðÔì[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£ºgongliangliu@126.com¿ÆÑй¤×÷:´ú±íÐÔ¿ÆÑÐÏîÄ¿1.¹ã¶« ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖÙâýũҵ¹¤³ÌѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÍõÇÙ
µ¼Ê¦ÐÕÃû£ºÍõÇÙÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º512ËùÊôԺУ£ºÖÙâýũҵ¹¤³ÌѧԺËùÊôԺϵ£ºÇṤʳƷѧԺְ³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÊ³Æ·¿ÆÑ§Ñо¿ÁìÓò£º¹ûÊßÖü²ØÓë¼Ó¹¤¡¢ÌìÈ»²úÎïÌáÈ¡ÓëÓ¦Óá¢Å©¸±²úÆ·¸ßÖµ»¯Éî¼Ó¹¤Ñо¿ÁìÓò£º¹ûÊßÖü²ØÓë¼Ó¹¤¡¢ÌìÈ»²úÎïÌáÈ¡ÓëÓ¦Óá¢Å©¸±²úÆ·¸ßÖµ»¯Éî¼Ó¹¤[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖÙâýũҵ¹¤³ÌѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÀîСÇÙ
µ¼Ê¦ÐÕÃû£ºÀîСÇÙÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º504ËùÊôԺУ£ºÖÙâýũҵ¹¤³ÌѧԺËùÊôԺϵ£ºÅ©ÒµÓëÉúÎïѧԺְ³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£º²©µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÖÖÖÊ×ÊÔ´±£»¤ÓëÀûÓÃÑо¿ÁìÓò£º×÷ÎïÒÅ´«ÓýÖÖÑо¿ÁìÓò£º×÷ÎïÒÅ´«ÓýÖÖ[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£ºxiaoqinli2000@126.com¿ÆÑй¤×÷:´ú±íÐÔ¿ÆÑÐÏîÄ¿1.¹ú ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖÙâýũҵ¹¤³ÌѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ËïÃú·É
µ¼Ê¦ÐÕÃû£ºËïÃú·ÉÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º499ËùÊôԺУ£ºÖÙâýũҵ¹¤³ÌѧԺËùÊôԺϵ£º¶¯Îï¿Æ¼¼Ñ§ÔºÖ°³Æ£ºÑо¿Ô±µ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º¼ÄÉú³æÐÂÒ©´´ÖÆÑо¿ÁìÓò£ºÔ¤·ÀÊÞҽѧÑо¿ÁìÓò£ºÔ¤·ÀÊÞҽѧ[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£ºsmf7810@126.com¿ÆÑй¤×÷:´ú±íÐÔ¿ÆÑÐÏîÄ¿1.?¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÏîÄ¿ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖÙâýũҵ¹¤³ÌѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-Áõ˫ӡ
µ¼Ê¦ÐÕÃû£ºÁõ˫ӡÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º479ËùÊôԺУ£ºÖÙâýũҵ¹¤³ÌѧԺËùÊôԺϵ£ºÐÅÏ¢¿ÆÑ§Óë¼¼ÊõѧԺְ³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÊ³Æ·°²È«ÓëÖÇÄÜ¿ØÖÆÑо¿ÁìÓò£ºÅ©ÒµÎïÁªÍø¡¢ÖÇÄÜÐÅÏ¢´¦Àí¡¢´óÊý¾ÝÍÚ¾òÑо¿ÁìÓò£ºÅ©ÒµÎïÁªÍø¡¢ÖÇÄÜÐÅÏ¢´¦Àí¡¢´óÊý¾ÝÍÚ¾ò[ÊÕÆð]ͨѶ·½Ê½:µç×ÓÓʼþ£ºshuangyinliu@126. ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖÙâýũҵ¹¤³ÌѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-³Âº£¹â
µ¼Ê¦ÐÕÃû£º³Âº£¹âÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º442ËùÊôԺУ£ºÖÙâýũҵ¹¤³ÌѧԺËùÊôԺϵ£ºÇṤʳƷѧԺְ³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÊ³Æ·¼Ó¹¤Ó밲ȫÑо¿ÁìÓò£ºÊ³Æ·¼Ó¹¤Ó밲ȫÑо¿ÁìÓò£ºÊ³Æ·¼Ó¹¤Ó밲ȫ[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£ºchg1508@163.com¿ÆÑй¤×÷:´ú±íÐÔ¿ÆÑÐÏîÄ¿1£®¹ãÖÝÊÐÃñÉú¿Æ¼¼ÑÐ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖÙâýũҵ¹¤³ÌѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÖìÁ¢Ñ§
µ¼Ê¦ÐÕÃû£ºÖìÁ¢Ñ§ÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º434ËùÊôԺУ£ºÖÙâýũҵ¹¤³ÌѧԺËùÊôԺϵ£º»úµç¹¤³ÌѧԺְ³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÅ©Òµ»úе»¯Ñо¿ÁìÓò£ºÅ©Òµ¹¤³ÌÑо¿ÁìÓò£ºÅ©Òµ¹¤³Ì[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£º**@qq.com¿ÆÑй¤×÷:´ú±íÐÔ¿ÆÑÐÏîÄ¿£¨Ö÷³Ö£©1.¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÏîÄ¿(»ùÓÚ¹ãÒ嶯Á¦Ñ§ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ºÓ±±½¨Öþ¹¤³ÌѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-Íõº£Áú\n
µ¼Ê¦ÐÕÃû£ºÍõº£ÁúÐÔ±ð£ºÈËÆøÖ¸Êý£º393ËùÊôԺУ£ººÓ±±½¨Öþ¹¤³ÌѧԺËùÊôԺϵ£ºÍÁľ¹¤³ÌѧԺְ³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£º²©µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÇÅÁºÓëËíµÀ¹¤³ÌÑо¿ÁìÓò£ºÇÅÁº¹¤³Ì¼°·À»¤¹¤³Ì£»Ó¦¼±½á¹¹¹¤³Ì£»ÇÅÁº½á¹¹°²È«ÐÔÆÀ¶¨¼°¿ìËÙÐÞ¸´¼Ó¹Ì¼¼Êõ£»´ò¿åÇÅÁºÕû¿×¼ÙÉè¼¼...[Õ¹¿ª]Ñо¿ÁìÓò£ºÇÅÁº¹¤³Ì¼°·À»¤¹¤³Ì£»Ó¦¼±½á¹¹¹¤³Ì£»ÇÅÁº½á¹¹ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖÙâýũҵ¹¤³ÌѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-Ê¢°®Îä
µ¼Ê¦ÐÕÃû£ºÊ¢°®ÎäÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º373ËùÊôԺУ£ºÖÙâýũҵ¹¤³ÌѧԺËùÊôԺϵ£ºÔ°ÒÕÔ°ÁÖѧԺְ³Æ£º½ÌÊÚµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÔ°ÁÖÖ²ÎïÓë¹ÛÉÍÔ°ÒÕÑо¿ÁìÓò£º»¨»Ü»¨ÆÚµ÷¿Ø¼°ÔÔÅàÉúÀíÑо¿ÁìÓò£º»¨»Ü»¨ÆÚµ÷¿Ø¼°ÔÔÅàÉúÀí[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£º**@qq.com¸öÈ˼òÊö:1998ÄêÄϾ©Å©Òµ´óѧ԰ÒÕ ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖÙâýũҵ¹¤³ÌѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÔøÏþ·¿
µ¼Ê¦ÐÕÃû£ºÔøÏþ·¿ÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º355ËùÊôԺУ£ºÖÙâýũҵ¹¤³ÌѧԺËùÊôԺϵ£ºÇṤʳƷѧԺְ³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÊ³Æ·¼Ó¹¤Ó밲ȫÑо¿ÁìÓò£ºÈâÆ·¼Ó¹¤ÓëÖÊÁ¿¿ØÖÆ¡¢Ê³Æ·ÓªÑøÓë´ó½¡¿µÑо¿ÁìÓò£ºÈâÆ·¼Ó¹¤ÓëÖÊÁ¿¿ØÖÆ¡¢Ê³Æ·ÓªÑøÓë´ó½¡¿µ[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£ºluckxf_zeng@16 ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ºÓ±±½¨Öþ¹¤³ÌѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÈÖ»¢ÈÊ\n
µ¼Ê¦ÐÕÃû£ºÈÖ»¢ÈÊÐÔ±ð£ºÈËÆøÖ¸Êý£º330ËùÊôԺУ£ººÓ±±½¨Öþ¹¤³ÌѧԺËùÊôԺϵ£ºÍÁľ¹¤³ÌѧԺְ³Æ£º½²Ê¦µ¼Ê¦ÀàÐÍ£ºÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÇÅÁºÓëËíµÀ¹¤³ÌÑо¿ÁìÓò£º£¨1£©ËíµÀΧÑÒÎȶ¨ÐÔ·ÖÎöÓë¿ØÖÆ£¨2£©ÑÒʯÁ¦Ñ§Ó빤³Ì¼Ó¹ÌÀíÂÛÓë¼¼Êõ£¨3£©ÆÆÁÑΧÑҵıäÐÎÐÐΪÑÐ...[Õ¹¿ª]Ñо¿ÁìÓò£º£¨1£©ËíµÀΧÑÒÎȶ¨ÐÔ·ÖÎöÓë¿ØÖÆ£¨2£©ÑÒʯÁ¦Ñ§Óë ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖÙâýũҵ¹¤³ÌѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-ÕÔÏþ¾ê
µ¼Ê¦ÐÕÃû£ºÕÔÏþ¾êÐÔ±ð£ºÅ®ÈËÆøÖ¸Êý£º320ËùÊôԺУ£ºÖÙâýũҵ¹¤³ÌѧԺËùÊôԺϵ£ºÇṤʳƷѧԺְ³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÊ³Æ·¼Ó¹¤Ó밲ȫÑо¿ÁìÓò£ºÊ³Æ·ÖÊÁ¿Ó밲ȫ¡¢µç·ÖÎö»¯Ñ§ºÍÉúÎï´«¸ÐÑо¿ÁìÓò£ºÊ³Æ·ÖÊÁ¿Ó밲ȫ¡¢µç·ÖÎö»¯Ñ§ºÍÉúÎï´«¸Ð[ÊÕÆð]ͨѶ·½Ê½:°ì¹«µç»°£º**µç×ÓÓʼþ£ºxiao0692@163.c ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27ÖÙâýũҵ¹¤³ÌѧԺöλÔÓéÀÖ¹Ù·½appÏÂÔØÑо¿Éúµ¼Ê¦¼ò½é-»Æå°È»
µ¼Ê¦ÐÕÃû£º»Æå°È»ÐÔ±ð£ºÄÐÈËÆøÖ¸Êý£º295ËùÊôԺУ£ºÖÙâýũҵ¹¤³ÌѧԺËùÊôԺϵ£º¾Ã³Ñ§ÔºÖ°³Æ£º¸±½ÌÊÚµ¼Ê¦ÀàÐÍ£ºË¶µ¼ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÅ©´åÓëÇøÓò·¢Õ¹Ñо¿ÁìÓò£ºÅ©²úÆ·ÎïÁ÷£¬¾ö²ß·ÖÎöÑо¿ÁìÓò£ºÅ©²úÆ·ÎïÁ÷£¬¾ö²ß·ÖÎö[ÊÕÆð]ͨѶ·½Ê½:µç×ÓÓʼþ£º**@qq.com¿ÆÑй¤×÷:´ú±íÐÔ¿ÆÑÐÏîÄ¿1.½ÌÓý²¿ÈËÎÄÉç¿ÆÇàÄê»ù½ðÏîÄ¿£¬Ö÷³Ö ...µ¼Ê¦ÐÅÏ¢ ±¾Õ¾Ð¡±à FreeöλÔÓéÀÖ¹Ù·½appÏÂÔØÍø 2019-05-27
